A prospective study to investigate clinical factors predicting hepatocarcinogenesis after the eradication of hepatitis C virus.

A prospective study to investigate clinical factors predicting hepatocarcinogenesis after the eradication of hepatitis C virus. - A study to investigate clinical factors predicting hepatocarcinogenesis after HCV eradication.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000028448

Enrollment

400

Registered

2017-12-01

Start date

2017-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic hepatitis or liver cirrhosis who have received interferon-free anti-HCV therapy with oral antivirals for serotype 1 or 2 HCV infection.

Exclusion criteria

Exclusion criteria: 1. Patients without any evaluation of the efficacy of anti-HCV therapy. 2. Patients whose clinical course after anti-HCV therapy cannot be tracked.

Design outcomes

Primary

Measure	Time frame
Clinical factors associated with hepatocarcinogenesis after HCV eradication.	—

Secondary

Measure	Time frame
Cancer-free survival time after HCV eradication	—

Countries

Japan

Contacts

Public ContactHaruhiko Takeda

Kyoto University Graduate School of Medicine Department of Gastroenterology and Hepatology

htakeda@kuhp.kyoto-u.ac.jp075-751-4319

Outcome results